NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis $2.90 -0.03 (-1.02%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.90 +0.00 (+0.17%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Altimmune Stock (NASDAQ:ALT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Altimmune alerts:Sign Up Key Stats Today's Range$2.88▼$3.0050-Day Range$2.60▼$3.6252-Week Range$2.56▼$7.73Volume1.99 million shsAverage Volume4.26 million shsMarket Capitalization$563.96 millionP/E RatioN/ADividend YieldN/APrice Target$16.67Consensus RatingModerate Buy Company Overview Altimmune, Inc. is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions. Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose. This candidate is being advanced in collaboration with the University of Alabama at Birmingham and is supported by the National Institute of Allergy and Infectious Diseases. In parallel, Altimmune’s HepTcell program aims to treat chronic hepatitis B by eliciting targeted T-cell responses capable of clearing infected liver cells. Altimmune’s AdCOVID™ platform uses a replication-incompetent adenovirus vector to deliver vaccine antigens directly to the nasal mucosa, and it is also under evaluation for additional respiratory pathogens, including coronaviruses. The company maintains a pipeline of preclinical programs in liver and metabolic diseases, reflecting its commitment to harnessing immunotherapy and vaccine design across multiple therapeutic areas. The company’s leadership team combines extensive scientific expertise and operational experience in vaccine research and development. Through a strategic blend of translational science and external partnerships, Altimmune seeks to advance innovative therapies that improve patient outcomes and address global health challenges.AI Generated. May Contain Errors. Read More Altimmune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreALT MarketRank™: Altimmune scored higher than 74% of companies evaluated by MarketBeat, and ranked 176th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialAltimmune has a consensus price target of $16.67, representing about 474.7% upside from its current price of $2.90.Amount of Analyst CoverageAltimmune has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Altimmune's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Altimmune are expected to decrease in the coming year, from ($0.69) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Altimmune's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.69% of the float of Altimmune has been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 4.93.Change versus previous monthShort interest in Altimmune has recently increased by 23.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.91 News SentimentAltimmune has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Altimmune this week, compared to 10 articles on an average week.Search Interest44 people have searched for ALT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows8 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Altimmune in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $88,500.00 in company stock, which represents 0.0157% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $88,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders1.60% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALT Stock News HeadlinesAltimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 22 at 2:14 AM | americanbankingnews.comAltimmune shares climb after first-quarter loss beats expectations (ALT)May 15, 2026 | finance.yahoo.comThe SpaceX filing is public. The window is closing.SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price.May 24 at 1:00 AM | Behind the Markets (Ad)Altimmune (NASDAQ:ALT) Given New $11.00 Price Target at Citizens JmpMay 15, 2026 | americanbankingnews.comAltimmune (ALT) Q1 2026 Earnings TranscriptMay 14, 2026 | finance.yahoo.comAltimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readoutMay 14, 2026 | seekingalpha.comAltimmune, Inc. (ALT) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comAltimmune shares rise over 3% on beating first quarter loss estimatesMay 13, 2026 | za.investing.comSee More Headlines ALT Stock Analysis - Frequently Asked Questions How have ALT shares performed this year? Altimmune's stock was trading at $3.61 at the beginning of 2026. Since then, ALT stock has decreased by 19.7% and is now trading at $2.90. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) issued its earnings results on Wednesday, May, 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.07. Altimmune had a negative net margin of 214,860.98% and a negative trailing twelve-month return on equity of 42.57%. Read the conference call transcript. When did Altimmune's stock split? Altimmune's stock reverse split on the morning of Friday, September 14th 2018.The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Altimmune's major shareholders? Altimmune's top institutional investors include Dimensional Fund Advisors LP (0.80%), Bank of America Corp DE (0.44%), Bank of New York Mellon Corp (0.32%) and Beirne Wealth Consulting Services LLC (0.32%). Insiders that own company stock include David Drutz, Jerome Benedict Durso, Gregory L Weaver, Wayne Pisano, John Gill and Diane Jorkasky. View institutional ownership trends. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY). Company Calendar Last Earnings5/13/2026Today5/24/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, ALT's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALT CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees50Year Founded1997Price Target and Rating Average Price Target for Altimmune$16.67 High Price Target$24.00 Low Price Target$11.00 Potential Upside/Downside+474.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.09 million Net Margins-214,860.98% Pretax Margin-253,002.78% Return on Equity-42.57% Return on Assets-35.57% Debt Debt-to-Equity Ratio0.12 Current Ratio29.56 Quick Ratio29.56 Sales & Book Value Annual Sales$40 thousand Price / Sales14,099.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.46 per share Price / Book1.99Miscellaneous Outstanding Shares194,470,000Free Float191,362,000Market Cap$563.96 million OptionableOptionable Beta0.18 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:ALT) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
